New blood test could improve how we monitor heart medications
NCT ID NCT04822363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new blood test (pDrp1 assay) to measure platelet activity in 112 healthy and severely obese volunteers taking aspirin or clopidogrel. The goal was to see if the new test is as accurate as the current standard test (light transmission aggregometry). Researchers also looked at how the drugs work over time. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aspirin and Clopidogrel
- What this could lead to
- If successful, this could provide a simpler, faster blood test to measure how well antiplatelet drugs work, helping doctors tailor treatments.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. The new test may not prove accurate enough or may not work in real-world clinical settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test